Tarsus Pharmaceuticals (TARS) Net Cash Flow (2019 - 2026)

Tarsus Pharmaceuticals' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$82.0 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 201.29% year-over-year to -$82.0 million in Q1 2026; TTM through Mar 2026 was -$74.2 million, a 382.95% decrease from a year earlier, with the FY2025 full-year figure at $88.8 million, up 169.63% from the prior year.
• Net Cash Flow fell to -$82.0 million in Q1 2026 per TARS's latest filing, from $70.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $119.9 million in Q3 2023 and bottomed at -$97.8 million in Q4 2022.
• The 5-year median for Net Cash Flow is -$4.9 million (2024), against an average of -$3.9 million.
• Across the five-year window, Net Cash Flow plunged 4469.8% in 2024 and surged 429.09% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$97.8 million in 2022, then jumped by 98.24% to -$1.7 million in 2023, then plunged by 4469.8% to -$78.8 million in 2024, then surged by 189.96% to $70.9 million in 2025, then tumbled by 215.64% to -$82.0 million in 2026.
• Per Business Quant, the three latest TARS Net Cash Flow figures stand at -$82.0 million (Q1 2026), $70.9 million (Q4 2025), and $16.1 million (Q3 2025).